Key facts
- This page summarizes Jack E. Stover's Form 3 filing for Transcode Therapeutics, Inc. (RNAZ).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 22 Dec 2025, 16:39.
Jack E. Stover - 19 Dec 2025 Form 3 Insider Report for Transcode Therapeutics, Inc. (RNAZ)
- Reporting relationship
- Director
- Issuer ticker
- RNAZ
- Reported as of
- 19 Dec 2025
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 22 Dec 2025, 16:39:09 UTC
- Prior SEC filing
- 16 Dec 2025
- Next SEC filing
- 30 Jan 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Thomas A. Fitzgerald, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jack E. Stover filed Form 3 for Transcode Therapeutics, Inc. (RNAZ) on 22 Dec 2025.
Change
- Previous filing in this sequence was filed on 16 Dec 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0001203603
Primary reporting owner
STOVER JACK E
- Relationship
- Director
- Address
- C/O TRANSCODE THERAPEUTICS, INC., 6 LIBERTY SQUARE, #2382, BOSTON
- Signature
- /s/ Thomas A. Fitzgerald, Attorney-in-Fact
- Signature date
- 22 Dec 2025
Additional SEC filing notes
Filing notes and footnotes
Ownership status
The filing reports no beneficially owned securities.
SEC remarks
Exhibit 24: Power of Attorney